KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non Operating Income (2016 - 2025)

Historic Non Operating Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $26.2 million.

  • CRISPR Therapeutics AG's Non Operating Income rose 468.0% to $26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.8 million, marking a year-over-year decrease of 636.16%. This contributed to the annual value of $103.9 million for FY2024, which is 4467.67% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Non Operating Income stood at $26.2 million, which was up 468.0% from $22.1 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Non Operating Income peaked at $28.0 million during Q4 2024, and registered a low of $363000.0 during Q1 2022.
  • For the 5-year period, CRISPR Therapeutics AG's Non Operating Income averaged around $14.0 million, with its median value being $13.5 million (2025).
  • In the last 5 years, CRISPR Therapeutics AG's Non Operating Income crashed by 8143.22% in 2022 and then soared by 341019.28% in 2023.
  • CRISPR Therapeutics AG's Non Operating Income (Quarter) stood at $2.2 million in 2021, then surged by 422.99% to $11.5 million in 2022, then soared by 74.04% to $20.0 million in 2023, then surged by 39.91% to $28.0 million in 2024, then dropped by 6.22% to $26.2 million in 2025.
  • Its Non Operating Income stands at $26.2 million for Q3 2025, versus $22.1 million for Q2 2025 and $13.5 million for Q1 2025.